RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
Company to capitalize on proprietary self-delivering RNAi platform (sd-rxRNA®) that has now been proven to be safe and effective in clinical trials
Partner/Out-license robust dermatology and ophthalmology franchises to strengthen the Company's balan... Biopharmaceuticals, Oncology RXi Pharmaceuticals
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Clinical Trials | Dermatology | Opthalmology | Pharmaceuticals | Skin